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Expression of vascular cell adhesion molecule.! (VCAM-1) in kidney
allograft rejection. VCAM- 1, a leukocyte adhesion molecule expressed
by cytokine-activated endothelial cells in culture, may mediate mono-
nuclear leukocyte infiltration in vessels and interstitium in solid organ
allograft rejection. Using the avidin-biotin immunoperoxidase tech-
nique and an affinity-purified rabbit polyclonal antisera to recombinant
human VCAM (rVCAM Ab) which works in methyl Carnoy's fixed
tissues, we studied the expression of this molecule in biopsies of
transplanted kidneys (N = 34) with and without features of rejection
and allograft nephrectomies (N = 17)as well as nontransplanted control
tissues (N = 26). The rVCAM Ab showed a population of reactive
endothelial cells limited to sites of prominent subendothelial leukocytic
cell infiltration in arteries and veins, and occasional peritubular capil-
laries (PTC) in rejecting allografts. Endothelial expression of VCAM
was rarely identified in biopsies showing interstitial rejection only or
cyclosporine toxicity, usually in PTC, and was only rarely encountered
in nontransplanted control tissues. Apparent de novo expression of
VCAM-l by arterial smooth muscle cells and mesangial cells was
present in cases of severe rejection. In addition, a population of cells
(DC) with dendritic morphology was identified by rVCAM Ab within
sites of lymphoid cell aggregation in rejecting allografts. Further evi-
dence that these cells represent true DC was obtained by identification
of VCAM-l positive, morphologically similar cells in both germinal
centers and interfollicular areas of all seven reactive lymph nodes
tested; and by similar staining of these cells in the ailografts and lymph
nodes by antibodies to nerve growth factor receptor and the comple-
ment receptor CR1, previously shown to recognize DC. DCs were
generally not seen in uninflamed normal control organs or portions of
allografts uninvolved by lymphoid aggregates. Enhanced tubular epi-
thelial cell expression of VCAM-1 was also present in rejecting al-
logi-afts. All staining could be abolished by absorption of the antisera
with VCAM-l transfected, but not ICAM-1 or ELAM-l transfected,
CHO cells, In situ hybridization studies utilizing a cDNA probe to
human VCAM-l demonstrated mRNA production by glomerular, tubu-
lar and vascular cells corresponding to sites where the protein was
immunohistochemically localized. This study provides evidence that:
(1) endotheljal cell expression of VCAM-l may define sites of acute
vascular inflammation in renal transplant rejection; (2) VCAM-l is
expressed by some arterial smooth muscle cells during vascular rejec-
tion; (3) VCAM-I expression by mesangial cells and tubular cells may
be upregulated in transplant rejection; and (4) there is probably a
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population of VCAM-l expressing DC that migrates into host kidneys
and participates in the cellular rejection process.
Acute vascular rejection in muscular arteries in renal a!-
lografts is characterized by subendothelial infiltration by effec-
tor immunocompetent and inflammatory cells, principally lym-
phocytes and monocyte/macrophages [11. Vascular (as well as
interstitial) rejection is often a focally distributed process, and
so it is important to define the mechanisms which determine the
sites of leukocyte attachment and migration through arterial
endothelium that initiate the rejection process. It has been
shown recently that a number of inflammatory or immune
mediators, such as interleukin-l (IL-i) and tumor necrosis
factor (TNF) can induce the expression of proteins on the
surface of cultured endothelial cells that act to increase the
adhesiveness of these cells for specific leukocyte populations,
including lymphocytes and monocytes [2, 31. Modulation of the
expression or configuration of such adhesion proteins on the
endothelium or similar modulation of the corresponding ligands
on circulating leukocytes might be especially important in
establishing the endothelial and subendothelial injury charac-
teristic of vascular rejection in solid organ allografts, and might
also be vital to localization of the intraparenchymal inflamma-
tory infiltrates mediating interstitial rejection in such allografts.
Currently, five endothelial proteins have been molecularly
cloned 14—91 and have been shown to be involved in leukocyte
adhesion in humans [10—141: E-selectin, endothelial leukocyte
adhesion molecule-i (ELAM- 1); P-selectin (platelet activation
dependent granule-external membrane, PADGEM; granule
membrane protein- 140, GMP- 140, CD62); intercellular adhe-
sion molecule-l (ICAM-l, CD54); ICAM-2; and vascular cell
adhesion molecule-I (VCAM-i, INCAM 110). Studies of
ICAM-l in human and experimental renal transplantation have
provided evidence of up-regulated expression of this molecule
on endothelial and tubular cells and indicated that leukocyte
binding to ICAM- 1 is an important component of both vascular
and interstitial rejection processes [15—201. A role for E-selectin
or P-selectin in renal allograft rejection has not been reported.
However, studies of VCAM-l in cardiac transplant biopsies
have localized up-regulated expression on capillary endothe-
hum which is associated with areas of mononuclear cell infil-
tration, suggesting a role for this molecule in binding leukocytes
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in viva and in determining the sites of active rejection [21, 221.
Recently, upregulated endothelial expression of VCAM-1 dur-
ing episodes of human pancreatic and hepatic allograft rejection
has also been demonstrated [23, 24]. Finally, a recent study by
Briscoe et a! has demonstrated up-regulated expression of
VCAM-l by tubular and vascular endothelial cells in a series of
eleven renal allograft biopsies [25]. One other study, using an
antibody to VCAM-l without documentation of its specificity,
has also reported on its expression in renal transplantation [26].
In this study, we have utilized a recently characterized poly-
clonal antiserum raised against recombinant human VCAM-1
(rVCAM) to evaluate the contribution of this molecule to renal
vascular rejection [231. In the present study we have established
that this antiserum recognizes an epitope that is preserved in
tissue fixed in methyl Carnoy's solution, evaluated the distri-
bution of the VCAM- I molecule in normal fixed and frozen
human kidney tissue, and identified sites of up-regulated
VCAM-1 expression in rejecting renal allografts. Our studies
confirm and expand on the findings of Briscoe et al by demon-
strating VCAM-l expression on arterial endothelial cells and
smooth muscle cells during the course of vascular rejection, and
demonstrate a population of VCAM-l expressing dendritic cells
within aggregates of leukocytes in rejecting allografts. The
application of in situ hybridization techniques allows us to
conclude the VCAM expression identified by each of these cell
types is the result of active local production of this peptide
rather than a result of passive, local entrapment or phagocytosis
of secreted or released VCAM-1 from other cells.
Methods
Tissue selection
A total of 34 renal allograft biopsies were utilized in this
study. Allograft biopsies were obtained as core needle biopsies,
and comprised the following categories: (1) 21 day protocol
biopsies in patients undergoing combined kidney and pancreas
transplantation (N = 7); (2) cases of acute cyclosporine neph-
rotoxicity as determined by subsequent clinical course and
compatible biopsy findings (N = 5); (3) cases of mild interstitial
inflammatory infiltration of uncertain significance, not clearly
related to rejection (N = 3); (4) cases of acute cellular rejection,
of at least moderate severity and demonstrating features of
tubulitis (N = 11); (5) cases of acute vascular rejection, as
previously illustrated [1] (N = 6); (6) and cases of chronic
rejection (N = 2). Allograft kidneys (N = 17) excised for
irreversible rejection were also utilized. These cases invariably
had features of cellular (interstitial) and vascular rejection. The
infiltrates of cellular rejection were usually of moderate to
severe intensity, but focally distributed within the renal paren-
chyma, so that portions of tissue showed only minimal inflam-
matory infiltration. Many of these nephrectomy specimens also
contained occasional, irregularly distributed lymphoid aggre-
gates similar to those previously described in other solid organ
allografts [19]. Arterial vessels showing intimal inflammation as
well as uninvolved vessels were distributed both in areas of
prominent interstitial inflammation and in areas in which this
process was mild and even absent.
All biopsies were obtained from patients under conditions of
routine immunosuppression protocols employing cyclosporine
and prednisone. The biopsies were obtained prior to more
specific or intensified therapies such as administration of OKT3
The nephrectomy specimens in general were exposed to multi-
ple courses of routine and intensified immunosuppression prior
to excision, and represent a heterogeneous sample from a
clinical standpoint.
Normal human kidney tissue (N = 23) was obtained from
kidneys surgically excised because of the presence of a local-
ized neoplasm. Tissues utilized for this study were obtained
from macroscopically normal portions of kidney located at
some distance from the neoplastic process. Additionally, nor-
mal tissue was obtained from fresh cadaver kidneys unable to
be utilized for transplantation (N = 3).
Because VCAM-l has been identified within dendritic cells in
lymphoid tissues [23, 271, the reactivity of the antisera used in
this investigation was also studied in seven reactive lymph
nodes and tonsils, surgically removed for lymphoid hyperpla-
sia.
All tissues were fixed in methyl Carnoy's fixative (60%
methanol, 30% chloroform, 10% acetic acid) for at least 12
hours and then processed, paraffin embedded, and sectioned
using conventional techniques.
Normal tissues were also snap frozen and utilized unfixed for
identical immunohistochemical studies to evaluate possible loss
of antibody sensitivity when studying the fixed tissues em-
ployed for the remainder of this study.
Immunohistochemistry
Briefly, sections of methyl Carnoy's fixed tissue were depar-
affinized with xylene and graded ethanol's, blocked with 3%
hydrogen peroxide, and washed with PBS (138 mM NaC1, 2.7
mM KCI, 3.2 m'vi Na2HPO4, 1.5 mM KH2PO4, pH 7.3). The
tissue was then incubated with one of the primary murine
monoclonal antibodies (see below), or rabbit polyclonal anti-
sera, and subsequently processed using a avidin-biotin immu-
noperoxidase method with 3,3'-diaminobenzidine (with nickel
enhancement) as the chomogen as previously described [28,
291. Sections were counterstained with methyl green or hema-
toxylin. For all samples, negative controls for the immunohis-
tochemica! procedures consisted of substitution of the primary
antibody with both irrelevant murine monoclonal antibodies, or
non-immune rabbit sera, and PBS. Positive controls included
concurrent staining of fixed human tonsil, a tissue with detect-
able constitutive expression of VCAM-l on dendritic cells [23,
271 as previously described, and fixed normal human kidney, a
tissue with detectable constitutive expression of VCAM-l on
parietal epithelial cells [271.
Antibodies
Vascular cell adhesion molecule-I. Rabbit polyclonal anti-
sera was raised against a recombinant form of human VCAM- 1
(rsVCAM) that was purified to homogeneity by immunoaffinity
chromatography as previously described [30]. NZW rabbits, 3
to 4 kg, were immunized with purified rsVCAM (1 mg), emul-
sified (1:1) in Freund's complete adjuvant (Difco Laboratories,
Detroit, Michigan, USA). The rabbits were boosted with
rsVCAM (1 mg) in incomplete adjuvant, at monthly (3x) and
then bimonthly intervals. Bleeds were taken 7 to 14 days after
each boost. Rabbit antisera was affinity purified by passage over
protein A, with the IgG fraction then passed over an affinity
resin of human rsVCAM-1 immobilized on Affigel (8 mg
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rsVCAM- 1 ml of resin). The antisera was eluted with buffer at
pH 3.0, dialyzed into PBS, aliquoted and stored at —80°C.
Absorption studies of VCAM-1. Reactivity and specificity of
this antibody in fixed tissues was established using methyl
Carnoy's fixed cell aggregates of Chinese hamster ovary cells
either transfected or untransfected (negative control) with
VCAM cDNA (provided by Dr. Margaret Rosa, Biogen, Cam-
bridge, Massachusetts, USA), which were then shown to ex-
press VCAM-1 at the cell surface by appropriate binding of
leukocyte cell lines as well as binding inhibition assays.
Further, Chinese hamster ovary (CHO) cells transfected with
VCAM-l, ICAM-1, and ELAM-l and demonstrating surface
expression of each of these molecules as well as untransfected
CHO cells, were maintained in culture as previously described
[30]. Culture plates were washed with PBS, scraped, and
pelleted after centrifugation at 1200 RPM. Cell pellets were
fixed in methyl Carnoy's solution, and processed and embedded
in paraffin for tissue immunohistochemistry using procedures
detailed above. The rabbit polyclonal antisera to recombinant
VCAM-1 was demonstrated to be reactive with the cell surface
of CHO cells transfected with VCAM-1, but not with untrans-
fected cells or those transfected with ICAM- I or ELAM- 1 (data
not shown).
Cell pellets, each containing approximately 25 x 106 total
cells, of VCAM-l, ICAM-l, and untransfected CHO cells were
also collected in serial dilutions of PBS, and then incubated for
60 minutes at room temperature with aliquots of rabbit poly-
clonal anti-VCAM-1 antisera. After incubation, the suspensions
were again centrifuged at 1200 RPM and the supernatants
collected for incubation on tissue sections of both the cell
pellets as noted above, and on methyl Carnoy's fixed tissue
sections of human tonsil. Identification of tissue binding was
determined with the avidin-biotin immunoperoxidase technique
detailed above, and tissues were counterstained with methyl
green.
Nerve growth factor receptor-5 antibody (NGFR5) and nerve
growth factor receptor-2 antibody (NGFR-2)/dendritic cell
markers. NGFR5 is a monoclonal antibody originally developed
to study the expression of p75 nerve growth factor receptor in
tumors and normal tissues [31]. Among normal tissues, in
addition to expected neural immunostaining, NGFR5 has been
demonstrated to react with several non-neural cell types, in-
cluding lymphoid follicular dendritic cells [31, 32]. NGFR2 is a
second murine monoclonal antibody with functional blocking
characteristics which targets epitopes of p75 nerve growth
factor receptor distinct from those recognized by NGFR-5 [33].
In this study we used the NGFR5 and NGFR2 antibodies as
independent confirmatory immunolocalization markers of den-
dritic cells in lymphoid aggregates. A fourth, commercially
available, antibody to follicular dendritic cells (DRC-1, Dako
Corporation, Carpinteria, California, USA) reactive with the
complement receptor CR1 (CD35) was also subsequently uti-
lized on those nephrectomy specimens and biopsy specimens
with sufficient tissue remaining after initial immunohistochem-
ical studies.
Leukocyte markers. Immunophenotypic characterization of
infiltrating leukocytes was performed as previously described
[1]. Commercially available antibodies were used to identify
populations of monocytes/macrophages (anti-CD68, monoclo-
nal antibody KP-l, Dako Corporation [34], T lymphocytes
(anti-CD3, Dako Corporation) [35], and B lymphocytes (anti-
CD2O, monoclonal antibody L26, Dako Corporation) [36, 37].
Endothelial markers. Endothelial cells were identified by
lectin binding studies using Ulex europaeus I lectin (Vector
Laboratories, Burlingame, California) as previously described
[38, 39].
Smooth muscle cell markers. Murine monoclonal antibody
a-SM-I (Dako Corp.) has been characterized by tissue immu-
nohistochemistry and Western blotting [40], and has been
previously demonstrated to recognize smooth muscle a-actin in
methyl Carnoy's fixed tissues [41, 42]. We have previously
demonstrated the specificity of the increased glomerular ex-
pression of a-smooth muscle actin expression detected by
tissue immunohistochemistry with this antibody by concurrent
Northern analysis for a-actin mRNA synthesis in isolated
glomeruli obtained in a rat model of mesangiolytic injury [41].
In situ hybridization
Riboprobe preparation. One microgram of 1.1 kilobase (kb)
fragment of the human VCAM-1 gene, including 0.3 kb of the
3'-untranslated region, in the expression vector was transcribed
into an antisense riboprobe using the T3 polymerase, as previ-
ously described [43], using 250 iCi35 S-UTP (New England
Nuclear) as the radioactive label. After a 60 minute incubation
at 37°C, the cDNA was digested by adding I U RQI DNase
(Promega) and incubation at 37°C for an additional 15 minutes.
Free nucleotides were separated using a sephadex G-50 col-
umn. A sense riboprobe was also transcribed for control
hybridizations from a 1.25 kb fragment of the human VCAM-l
gene using T7 polymerase. Probes were stored at —70°C and
used within seven days of synthesis.
In situ hybridization. Arterial tissue from nephrectomy spec-
imens which had been fixed in 10% neutral buffered formalin
and embedded in paraffin were deparaffinized according to
standard protocal. In situ hybridization was then performed as
previously described [43, 44]. After the tissue was air dried, it
was dipped in NTB2 nuclear emulsion (Kodak) and exposed in
the dark at 4°C for one to two weeks. After developing, sections
were counterstained with hematoxylin and eosin. Controls
included simultaneous procedures performed on replicate sec-
tions using the sense riboprobe described above, and the use of
fixed cell pellets of the VCAM-l transfected and untransfected
CHO cells as additional positive and negative controls.
Double labeling immunocytochemistry
Methyl Carnoy's fixed, paraffin embedded tissues were sec-
tioned and mounted on aminopropylmethoxysilane (APTS)
coated slides. After deparaffinization and rehydration, the
slides were incubated with rabbit-anti-VCAM-1 diluted in PBS
plus 1% BSA overnight at 4°C. After washing, sections were
incubated with goat-anti-rabbit IgG-gold (Amersham, Arlington
Heights, Illinois, USA) diluted in PBS plus 1% BSA and 0.1%
gelatin for one hour at room temperature. Sections were
washed, and the gold was visualized with an intense M silver
enhancement kit (Amersham). The sections were then incu-
bated sequentially with: (1) anti-a-smooth muscle actin or
anti-CD-68; (2) biotinytated horse-anti-mouse IgG (Vector Lab-
oratories, Burlingame California, USA); and (3) avidin-biotin-
alkaline phosphatase complex (Vector laboratories). The alka-
line phosphatase was developed with a red substrate kit (Vector
V•1
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Fig. 1. (A) Normal human kidney i,nmunoreacted with anti-VCAM-1 antisera, There is strong expression of VCAM-l by glomerular parietal
epithelium, but not by other glomerular structures, interstitium, or adjacent muscular artery. (B) Normal human kidney. Focally, VCAM-l
expression by peritubular capillary endothelium was present. Although not present in this section, focal basolateral expression of VCAM-l by
tubular epithelium was also present. A, 75><. B, 220x.
Fig. 2. Arterial expression of VCAM-l in vascular rejection. (A) Muscular artery with acute rejection showing lifting of the endothelium and
subendothelial accumulation of mononuclear inflammatory cells. No neointimal proliferation characteristic of chronic vascular rejection is present.
(B) Large muscular renal artery with features of both acute (inflammatory infiltration) and chronic (neointimal proliferation) vascular rejection,
double labeled for VCAM expression in black (immunogold technique) and a smooth muscle actin in red (alkaline phosphatase technique). The
wall of another muscular artery segment incompletely profiled in this plane of section is present in the lower left portion of the photograph. (C)
Higher power view of artery shown in 2B shows acute changes of endothelial swelling and subendothelial and intimal infiltration by leukocytes.
Hematoxylin and eosin. (D) Higher power view of artery in B. There is prominent expression of VCAM-l by swollen endothelium, and well as
co-localization of VCAM-1 expression and actin expression by some neointimal smooth muscle cells (arrows). (E) Same artery and double label
technique as D, except the primary anti-VCAM-l antisera has been replaced by antisera absorbed with VCAM-l expressing CHO cells. The
VCAM-l staining of endothelial and smooth muscle cells has been abolished, but a-actin staining is unchanged. (F) Same artery as in C through
E. Double labeling shows VCAM-l expression in black, and an infiltrating population of CD68 monocytes/macrophages in red. (G, H) Chronic
vascular rejection in a smaller interlobular muscular artery from a different case than A or C, double labeled for VCAM-l in black and a-actin in
red. Colocalization of VCAM-l and a-actin expression to smooth cells is again apparent in G, with VCAM-l localization in these cells and the
endothelial cells again abolished with the use of an absorbed sera in H. A, C-H, 220x. B, 60x. Reproduction of this figure in color was made
possible through support from Biogen, Inc.. Cambridge, Massachusetts. USA.
Laboratories) and the slides were counterstained with methyl
green. Negative controls included substituting anti-VCAM-l
antibody which had been absorbed with VCAM-l positive CHO
cells for the primary anti-VCAM-l antibody, and substituting
normal mouse IgG for the anti-a-smooth muscle actin and
anti-CD-68.
Results
Normal kidney
Our immunohistochemical studies revealed that a detectable
level of VCAM- 1 is only rarely expressed by endothelial cells
lining arterial, venous, peritubular capillary, or glomerular
capillary beds in normal kidney. Rare expression by arterial
endothelium, usually involving only a single vessel within a
large histology sample obtained from a nephrectomy, was
present in 6 of 26 cases. The only kidney structure which
reliably expresses significant amounts of VCAM-1 is glomerular
parietal epithelium (Fig. 1A), a pattern identical to that de-
scribed by Rice et al in a study on frozen kidney tissues using a
different antibody reactive with the VCAM-1 molecule [27].
This finding, while of unknown significance, proved useful in
the study of transplant specimens as an internal positive control
for assessing the adequacy of immunostaining procedures and
interpreting the validity of otherwise negative results. A more
variable finding was VCAM-l expression by tubular epithelial
cells, a finding found in a minority (generally less than 10%) of
such tubular segments in 60% of the normal kidneys studied.
Occasionally, regional VCAM- I expression by peritubular cap-
illaries could be identified (Fig. lB). Staining patterns were
similar in frozen and fixed kidney sections, but with appreciably
better morphologic preservation in the fixed tissues.
Transplant kidney biopsies without rejection
Patterns of VCAM- 1 expression in the kidneys was generally
similar to those encountered in normal kidneys. VCAM-1
expression by arterial endothelium, smooth muscle cells, or
mesangial cells specifically was not a feature of the protocol
transplant biopsies or those showing mild inflammatory infiltra-
tion of uncertain significance. The biopsies indicative of cyclo-
sporine toxicity were noteworthy for one case with widespread
VCAM-l expression by tubular segments, and a second case
showing VCAM- 1 expression by arterial endothelium in a single
muscular artery segment without evidence of inflammatory cell
infiltration. Clinical follow-up of the first of these two cases
confirmed the diagnosis of cyclosporine toxicity; no immediate
clinical episodes of rejection subsequent to biopsy occurred.
The second patient whose biopsy showed focal arterial expres-
sion of VCAM- 1 developed a severe episode of biopsy-proven
vascular rejection less than one month after this initial biopsy.
The later biopsy was submitted fixed in its entirety in formalin,
and VCAM- 1 expression could not be ascertained.
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Transplant kidneys with features of rejection of five distinct sites of VCAM-l expression in rejecting kidney.
The first and most striking pattern of VCAM- 1 expression
The variety of forms and chronologic stages of injury present involved the arterial vasculature. Focal, but frequently pro-
in the tissues available for this study allowed the identification nounced staining of the endothelial lining of muscular arteries
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could be identified in those vessels showing features of acute
vascular rejection, that is, with features of endothelial separa-
tion from the underlying intima and/or internal elastic mem-
brane, adherence of mononuclear leukocytes to damaged endo-
thelium, and the subendothelial infiltration of mononuclear
leukocytes (Fig. 2). Such expression of VCAM-l was typically
more widespread and characterized by more intense staining
than the isolated arterial expression noted in the normal kidneys
and single cyclosporine nephrotoxicity case noted above. The
endothelial expression of VCAM-l was determined by obvious
morphologic appearance and location of cells reactive with the
VCAM-l antisera, as well as similar staining patterns obtained
in replicate sections in which endothelial binding by the lectin
Ulex I was assessed. Immunophenotypic characterization of
the infiltrating leukocytes within the arterial intima revealed
that virtually all could be identified as belonging to T-lympho-
cyte (CD3) and/or monocyte/macrophage (CD68), but not
B-cell (CD2O) lineages. Only occasional instances of peritubu-
lar capillary expression of VCAM-l could be identified, often in
or near areas of prominent cellular rejection with extensive
interstitial aggregation of mononuclear leukocytes.
Some arterial vessels with features of both acute rejection
and more chronic neointimal sclerosing changes (chronic vas-
cular rejection) showed expression of VCAM-l by non-leuko-
cytic spindled cells present in the neointima as well as variable
expression by the smooth muscle cells comprising the media of
these vessels (Fig. 2B-H). Double immunolabeling of histologic
sections with a monoclonal antibody to the smooth muscle cell
marker a-smooth muscle actin, and the anti-VCAM-l antisera,
demonstrated that these spindled cells were smooth muscle
cells (Fig. 2). VCAM-l expression by smooth muscle cells,
often, but not invariably, was accompanied by adjacent infiltra-
tion of the tissue of arterial neointima by T cells and monocyte/
macrophages. VCAM-l expression by medial smooth muscle
cells was generally not accompanied by inflammatory cell
infiltration. More specific histologic patterns which corre-
sponded to VCAM-l expression by arterial smooth muscle cells
were not discerned.
The second pattern of VCAM-l expression was identified
within the large tissue samples provided by allograft nephrec-
tomies, and was related to the presence of occasional, distinct
interstitial lymphoid aggregates, which by immunophenotypic
characterization usually could be shown to be predominantly
composed of T cells (CD3) with a smaller number of B cells
(CD2O) (Fig. 3). Less commonly, these aggregates contained a
more prominent B cell component, comprising up to half of the
cells present (Fig. 3D). Within these aggregates was a small but
distinct population of cells with dendritic morphology which
showed focally prominent expression of VCAM-l (Fig. 3B),
NGFR (Fig. 3E) and CD3S (not shown). By both morphologic
appearance and this immunohistochemical characterization,
these cells could be identified as dendritic cells similar to those
found in lymph nodes and tonsils.
The third pattern of VCAM-l expression was focal expres-
sion by glomerular mesangial cells (Fig. 4). Double immunola-
beling techniques generally revealed that most VCAM-l ex-
pressing mesangial cells also expressed a-smooth muscle actin
(Fig. 4B), a finding that has been shown previously to correlate
with mesangial cell injury or activation in both experimental
animals and humans [41, 42]. This pattern of mesangial cell
expression of VCAM- 1 was most prominent in cases also
showing VCAM-l expression by vascular smooth muscle cells.
It was not associated with specific glomerular abnormalities
such as glomerulonephritis or acute allograft glomerulopathy;
no cases exhibiting these features were available for this study.
The fourth pattern of VCAM-l expression included the
persistent widespread expression without discernible changes
from normal kidneys of VCAM- 1 by glomerular parietal epithe-
hal cells. The fifth pattern was the persistent and frequently
upregulated expression of VCAM-l by a subpopulation of
tubular cells (Figs. 4A, 5). This tubular expression was more
widespread in the allograft nephrectomies as compared with
normal kidneys, which were the pathologic specimens where
the amount of tissue available for examination allowed for such
comparisons to be made. Tubular expression was typically
basolateral in distribution (Fig. 4A), although at times VCAM-l
expression was detected over the entire cell surface. In some
cases tubules expressing VCAM-l could be identified as prox-
imal tubules; most often a distinction between proximal and
distal tubular cell expression could not be made because of the
extent of tissue injury. In most allograft kidneys, VCAM-l
expression involved only a minority of the tubular segments and
could not be clearly correlated with concomitant features of
infiltration of tubular segments by mononuclear leukocytes. In
most rejection biopsies, however, tubular expression of
VCAM-l was clearly more extensive than control biopsies and
was in some cases widespread. Such cases often, but not
always, had adjacent accumulations of inflammatory cells in the
interstitium.
Studies in which the primary antisera to VCAM-l was
replaced by PBS or non-immune rabbit serum, or when the
primary antisera was absorbed with VCAM-l expressing CHO
cells, resulted in abolishing the specific staining patterns de-
scribed above (Fig. 2E, H).
In situ hybridization
The in situ hybridization procedures revealed that cell types
previously identified as expressing VCAM-l by immunocyto-
chemical techniques also expressed mRNA for VCAM-l. Spe-
cifically, in rejecting kidneys, the VCAM-l probe hybridized to
mesangial and parietal epithelial cells within the glomerulus,
arterial endothelium and neointimal smooth muscle cells in
arteries demonstrating acute and chronic rejection, and epithe-
ha! cells of the distal tubules (Fig. 6). The VCAM-l mRNA
probe also hybridized to lymphoid aggregates in allografts in a
distribution consistent with production by dendritic cells. How-
ever, because of the compressed cellularity of these aggregates,
the fact that dendritic cells extend thin cell processes through-
out the aggregates, and the lack of distinct morphologic features
of dendritic cells, the radioisotopic labeling could not be un-
equivocally localized solely to dendritic cells in these areas.
Discussion
This study adds to a growing body of evidence that VCAM-l
expression is up-regulated in the course of solid organ trans-
plant rejection 12 1—26]. In kidney ahlografts, VCAM-1 may be
expressed by multiple cell types, including parietal epithehial
cells and mesangial cells in the glomerulus, endothehial cells and
smooth muscle cells of the arterial wall, endothehial cells of the
interstitial capillaries, dendritic cells within the interstitium,
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Fig. 3. (A) Advanced allograft rejection; with an interstitial lymphoid aggregate. (B) A population of dendritic cells expressing VCAM-l within
this aggregate. (C) Many CD3 T-lymphocytes are present in this aggregate. (D) Many L26 B-celJs are also present in this aggregate, although
the number of B cells encountered in such aggregates is usually less. (E) A similar lymphoid aggregate showing expression of p75 nerve growth
factor receptor (NGFR) by the same dendritic cells that express VCAM- I. (F) Another lymphoid aggregate in a renal allograft biopsy different from
that illustrated in D and E showing expression of VCAM-1. (G) Replicate (but not immediately adjacent) section of the same lymphoid aggregate
illustrated in F showing expression of NGFR by same dendritic cells seen to express VCAM-l. A, lIOx. B-D, 330x. E, 220x. F, G, 330x.
Reproduction of this figure in color was made possible through support from Biogen, Inc., Cambridge, Massachusetts, USA.
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Fig. 4. (A) Glomerular expression of VCAM-I in a case of severe rejection. Prominent parietal epithelial cell expression of VCAM-l persists, while
mesangial expression is now prominent. Adjacent tubules show enhanced, basolateral expression of VCAM-l as well. (B) Double labeling of
glomerulus from same case shows VCAM-l expression in black, a-actin expression in red. The up-regulated expression of VCAM-l by mesangial
cells is accompanied by up-regulated expression of cx-actin. A, 220x. B, 330x. Reproduction of this figure in color was made possible through
support from Biogen, Inc., Cambridge, Massachusetts, USA.
Fig. 5. Same case but different artery as in Figure 2A. There is an
adjacent population of tubular cells showing up-regulated expression
VCAM-l, with staining intensity most pronounced at the basolateral
surface. bOx.
and some tubular epithelial cells. The expression of VCAM-l
by two of these cell types in human kidneys—the vascular
smooth muscle cell and a population of interstitial dendritic
cells indistinguishable from those identified in lymphoid organs
and lymphoid aggregates in other sites—has not been recog-
nized previously. Because VCAM-1 appears to have known
biologic functions that serve both to recruit and activate certain
classes of leukocytes, the up-regulated expression of VCAM-1
at specific tissue sites of injury suggest mechanisms that may
account for the focality of the leukocytic accumulation and
tissue injury that is characteristic of transplant rejection.
Perhaps the most striking finding of this study is the VCAM- I
expression in muscular arteries engaged in acute and chronic
vascular rejection. This study demonstrates that VCAM-l
expression can be identified on muscular artery endothelium at
the time of acute vascular rejection, and can be localized to
areas where T cells and monocyte/macrophages infiltrate and
accumulate in the subendothelial space. This finding under-
scores the significance of the endothelial VCAM-1 expression,
because it is T lymphocytes and monocytes/macrophages which
are among the leukocyte subpopulations which constitutively
express the VLA-4 integrin (CD49dICD29) on their cell surface,
and hence would be the cell populations expected to adhere to
cells with surface VCAM-1 expression [2, 3]. The endothelial
expression of VCAM-l in muscular arteries is only rarely seen
in the cohort of normal tissues, and it is only rarely present in
the cohort of transplant biopsies without detectable rejection.
These findings provide evidence for a role for up-regulated
expression VCAM-l in attracting specific leukocyte popula-
tions to parenchymal sites of rejection.
Equally striking in this study is the prominent expression of
VCAM-1 by smooth muscle cells of the entire vascular tree.
VCAM-1 was focally present in both large and small arteries,
and expression focally extended even to individual glomerular
arterioles in nephrectomy specimens removed for severe, irre-
versible rejection. The neointimal proliferation characteristic of
chronic vascular rejection was especially notable for expression
of VCAM- 1. Double immunolabeling procedures allowed us to
ascertain a-actin expressing smooth muscle cells were the
principle cell type expressing VCAM-l in this locale. Our in situ
hybridization studies indicate this expression of VCAM- 1 is due
to active synthesis of this peptide rather than non-specific
adherence or endocytosis of VCAM-l secreted by other cells
such as circulating leukocytes.
The significance of VCAM- 1 expression by vascular smooth
muscle cells is uncertain. However, smooth muscle cell expres-
sion of VCAM- 1 has been recently recognized in other settings
of vascular injury, notably atherosclerosis in humans [44] and in
a primate model of dermal injury mediated by the cytokines
tumor necrosis factor and IL-4 [45]. Based on the observation
that elevated VCAM-1 expression by smooth muscle cells in
human atherosclerosis may be associated with focal inflamma-
tion of the plaque, it has been proposed that this up-regulated
expression as well as up-regulated smooth muscle cell expres-
sion of other molecules important in the immune response such
as class II MHC peptides may be reflective of an "activated"
state that allows the smooth muscle cell to participate in the
immune/inflammatory response.
A third principal finding is the identification of VCAM- 1
expressing dendritic cells within lymphoid aggregates that were
present in some nephrectomy specimens. We and others have
previously demonstrated VCAM-1 expression on both follicular
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Fig. 6. (A) Low power view of,nuscular artery from allograft nephrectomy studied by in situ hybridization with antisence probes for VCAM-1
mRNA. There are features of neointimal proliferation (chronic rejection) and superimposed acute rejection (endothelial swelling, inflammatory cell
infiltration). (B) Same artery as A. VCAM-I mRNA protection in endothelial cells is evident by discrete localization of grains indicative of
hybridized probe. (C) Same artery as B, hybridization with a control sense probe to VCAM-l mRNA. No discrete hybridization is detected. (D)
Small muscular artery with features of acute vascular rejection, again showing prominent endothelial production of VCAM-l mRNA. (E) Allograft
kidney with prominent VCAM-I mRNA production by glomerular parietal epithelial cells (arrows) and tubular epithelial cells (arrowheads). No
specific hybridization was detected using control sense probes to VCAM-l. A, 60x. B-D, 600x. E, 360x. Reproduction of this figure in color was
made possible through support from Biogen, Inc., Cambridge, Massachusetts, USA.
dendritic cells and interdigitating cells in T cell dependent areas
of lymph nodes [23, 27, 46, 47]. Further, we have demonstrated
that prominent numbers of VCAM-l expressing dendritic cells
can be identified within lymphoid aggregates in rejecting liver
and pancreas allografts [23]. Others have found similar cells in
lymphoid aggregates occasionally encountered in inflamed sy-
novial tissue [48]. The lymphoid aggregates identified iii this
study were indistinguishable morphologically from those en-
countered and illustrated in our prior studies of liver and
pancreas rejection [23]. Immunohistochemical characterization
of the VCAM-l expressing dendritic cells in kidneys showed
they also typically express the p75 nerve growth factor receptor
and C3b complement receptor (CD35) similar to follicular
dendritic cells encountered in other lymphoid tissues [31, 32,
49]. Finally, our studies of normal and non-rejecting allograft
biopsies failed to detect a stable population of VCAM- 1 ex-
pressing dendritic cells within the kidney parenchyma, which is
in agreement with others [27, 50]. Therefore, such cells must
either migrate from host lymphoid tissues to the kidney allograft
at times of rejection, or a constitutive population of such cells
H
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must undergo phenotypic modulation from VCAM-1 - to
VCAM-1 in the course of active rejection. We emphasize that
this last possibility is at present theoretical; we know of no
direct evidence that such modulation may occur in dendritic
cells.
Given the infrequency with which lymphoid aggregates are
encountered in routine kidney allograft biopsies demonstrating
rejection, the role of dendritic cells and these aggregates in
mediating rejection may be open to question. However, evi-
dence that dendritic cells may have biologic functions important
to the rejection response come from studies that VCAM-1
expression by follicular dendritic cells promotes adhesion of
lymphoid cells, and hence may help further localize immuno-
competent cells to sites of immune injury [46, 49]. In addition,
studies by several groups of investigators have demonstrated
that VCAM-1 interactions with lymphocytes extend beyond
enhanced leukocyte adhesion. These studies suggest the
VCAM-1/VLA4 binding process provides additional co-stimu-
latory activation of resting T cells beyond that provided by
antigen and MHC class II molecules, thus providing a means to
amplify or promote immune reactions mediating allograft rejec-
tion [5 1—53]. Based on previous studies of the biology of
dendritic cells, it is also likely that VCAM-l expressing den-
dritic cells directly present foreign antigens to alloreactive
immune cells. Taken together with the localization data pre-
sented in this study, there is now sufficient evidence to suggest
VCAM—1 expressing dendritic cells may participate in local
recruitment and activation of lymphocytes in rejecting kidney
allografts.
In agreement with others, basolateral tubular expression of
VCAM-l was focally identified in normal kidneys, and was
up-regulated in rejecting kidneys as determined both by number
of involved tubular segments and by a subjective assessment of
increased staining intensity [25, 26]. Differences between our
findings and those illustrated by Briscoe et al were that we
usually did not find evidence of VCAM-1 expression by a
majority of tubular segments in rejecting allografts [25]. The
somewhat lesser extent of tubular VCAM expression encoun-
tered in our study may have been due to the use of fixed tissues,
with some resultant loss of antigenicity, in contrast to the
unfixed frozen tissue sections utilized by those investigators
and others [25, 26].
In addition to transplant rejection, enhanced tubular expres-
sion of VCAM-1 has been described in human drug-induced
tubulointerstitial nephritis, in experimental models of lupus
nephritis, and in cultured cells [54-56]. Although evidence is
somewhat scanty at present, it has been proposed that renal
tubular epithelial cells may present antigen to immunocompe-
tent cells and that furthermore, by their expression of leuko-
cytic adhesion molecules, may further promote and localize
immune/inflammatory injury in the kidney [57, 581. This study
lends support to this scenario being an important mechanism in
renal transplant rejection.
In agreement with others, glomerular expression of VCAM-l
by parietal epithelial cells and induced expression by mesangial
cells was also identified in this study [25, 27, 50]. The mesangial
cell expression was noteworthy because it occurred in conjunc-
tion with up-regulated mesangial expression of a-smooth mus-
cle actin, a cytoskeletal protein previously shown to be up-
regulated in the course of mesangial injury or activation [41,
42]. Up-regulated mesangial cell expression of VCAM- 1 in vitro
has been shown in response to cytokines and inflammatory
stimuli [59]. Although the mesangial cell is not commonly
thought to have a major role in mediating transplant rejection, it
is possible the up-regulated VCAM-1 expression we and others
have identified may help explain how monocytes/macrophages
often become concentrated in glomeruli during severe rejection
[1, 39].
In summary, we have provided evidence that: (1) expression
of VCAM-l by endothelial cells and other renal cell types may
define sites of acute inflammation in renal transplant rejection;
(2) smooth muscle cells in injured muscular arteries may
express VCAM-1, and (3) there is probably a population of
VCAM-l expressing dendritic cells that migrates into host
kidneys and participates in the cellular rejection process. Due
to the nature of a static morphology study, our findings can not
distinquish between the possibility that the VCAM-1 expression
identified is a primary mechanistic process for recruiting and
activating leukocytes within the rejecting kidney versus the
alternate possibility that VCAM-1 expression is a secondary
response induced by a population of activated leukocytes
already present within the parenchyma. Some evidence in
experimental models of transplantation indicate a primary role
for VCAM- 1. Interruption of the binding of endothelial
VCAM- 1 with integrin counter receptors on leukocytes in these
models appears to ameliorate the inflammatory response [60,
61]. The relative importance of VCAM-l expression by various
renal cell types in comparison to expression of other molecules
such as ICAM-l was also not addressed by our study. We
believe these questions in humans may be resolved by protocol
biopsy studies, in which early expression of VCAM-1 or related
leukocyte adhesion molecules may predict subsequent occur-
rences of clinically detectable rejection. Such studies are cur-
rently in progress.
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